Key Drivers
- Cash conversion
- Heavy leverage
- Premium valuation
AIAI Summary
Amgen now looks more like a transitioning growth platform than a pure mature biotech, with six drivers already powering ~70% of sales and lifting guidance, but the stock remains a show-me story because heavy debt, patent erosion, and uneven price action mean sustained execution is still needed to justify the valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash conversion
- •Heavy leverage
- •Premium valuation
AMGN remains highly profitable with strong cash conversion and dividend support, but heavy leverage, thin liquidity, and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Weak rebound
AMGN has drifted lower over the last month into a short-term downtrend, with support forming around $321-$327 but rebounds still stalling below $333.8-$343.7. ക
The bounce to $333.93 on 2026-05-13 faded quickly, reinforcing weak near-term momentum
Sentiment & News
Key News Insights:
- •Q1 Beat
- •Manufacturing Expansion
- •Valuation Caution
Amgen posted solid Q1 earnings momentum and expanded U.S. manufacturing investment, but valuation-focused analysis still largely suggests the stock may be priced above intrinsic value.
The news supports a constructive operating outlook for Amgen, though share-price upside may be limited until valuation concerns ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings